Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib Plus Vorinostat for NF1-Associated MPNST
NCT06693284Phase 1Recruiting
- Sponsor
- University of Minnesota
- Start
- Nov 2025
- Primary completion
- Jan 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mirdametinib and vorinostat in malignant peripheral nerve sheath tumor (MPNST), sponsored by University of Minnesota. Primary endpoints: Toxicity of the combination of mirdametinib and vorinostat at 48 months, Response of therapeutic targets at 48 months and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
mirdametinibvorinostat
03
Conditions
malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT06693284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693284.